Navtemadlin Enhances Glioblastoma Treatment
This is a news story, published by ScienceDaily, that relates primarily to Navtemadlin news.
disease research news
For more disease research news, you can click here:
more disease research newsScienceDaily news
For more news from ScienceDaily, you can click here:
more news from ScienceDailyAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like disease research news, you might also like this article about
MDM2 inhibitor. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest glioblastoma news, brain cancer news, disease research news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
glioblastoma cellsScienceDaily
•Health
Health
Study reveals activity of navtemadlin in glioblastoma, points to possible treatment improvements

79% Informative
Navtemadlin is an MDM2 inhibitor that can help to kill cancer cells by boosting the activity of p53, a protein that controls cell growth and induces cell death in response to DNA damage.
In lab experiments, the researchers found that navTemadlin was one of the best drugs at killing glioblastoma cells with intact, non-mutant p53.
VR Score
88
Informative language
93
Neutral language
63
Article tone
formal
Language
English
Language complexity
75
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links
Small business owner?